The Eli Lily logo is shown on one of the company’s offices in San Diego, California on 17 September, 2020.
Mike Blake | Roots
Ellie lily On Thursday, its 2025 guidance increased and posted the second quarter’s earnings, which estimated the strong demand for blockbuster weight loss and diabetes drugs.
The company increased its financial 2025 sales guidance from $ 60 billion to $ 62 billion to $ 58 billion to increase its business from $ 61 billion to $ 62 billion on the underlying strength in its business. The pharmaceutical giant also hopes that its adjusted FY 2025 will be earned between $ 21.75 to $ 23, with a previous guidance of $ 20.78 and $ 22.28 per share.
Elli Lily said that guidance does not include the employed tariffs of President Donald Trump on imported pharmaceuticals in the US.
Elli Lily’s weight loss drug zipbound and diabetes treatment, which shares the same active ingredient, defeat Wall Street’s expectations for the second quarter.
In addition, on Thursday, Elli Lily released a long time awaited Delayed test data Its experimental obesity pill, on Orforglipron, the highest dose, in which patients were helped to lose more than 12% of their body weight. This came under the expectations of Wall Street, sending more than 12% shares in premarket trading on Thursday.
Here Eli Lily reported on a survey of analysts by LSEG compared to the Wall Street expected for the second quarter:
- earnings per share: $ 6.31 adjusted vs $ 5.57 expected
- Income: $ 15.56 billion vs $ 14.71 billion is expected
The company posted a second quarter revenue of up to 38% from the same period a year ago, the second quarter of $ 15.56 billion.
Sales in the US rose 38% to $ 10.81 billion. Elli Lily stated that a 46% increase in volume – or the number of tips or units sold – for their products, mainly for Munjaro and Zapebound. The company said that the prices of low drugs were partially offset.
The pharmaceutical giant booked a net income of $ 5.66 billion, or $ 6.29 per share for the second quarter. It compares with a net income of $ 2.97 billion, or $ 3.28 per share a year ago.
Except for the one -time items associated with the value of abstract property and other adjustments, Eli Lily posted an income of $ 6.31 per share for the second quarter.
Results also come as Ellie Lily and other drug manufacturers for L.Evites on pharmaceuticals Imported in America and face Their call to reduce drug prices In the country.
President sent Letter Eli Lily and other companies call them last week and take steps to reduce drug prices by 29 September. After Trump in May, the move signed an executive order to revive a controversial scheme, the “most preferred nation” policy, which aims Slash drug cost To reduce the prices of some drugs in the US significantly abroad.
